<DOC>
	<DOCNO>NCT00003809</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Monoclonal antibody locate cancer cell either kill deliver tumor-killing substance without harm normal cell . It yet know whether cisplatin plus monoclonal antibody therapy effective cisplatin alone metastatic recurrent head neck cancer . PURPOSE : Randomized double-blinded phase III trial compare effectiveness cisplatin without monoclonal antibody treat patient metastatic recurrent head neck cancer .</brief_summary>
	<brief_title>Cisplatin With Without Monoclonal Antibody Therapy Treating Patients With Metastatic Recurrent Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Compare efficacy ( survival response rate ) toxicity cisplatin without monoclonal antibody C225 patient metastatic and/or recurrent squamous cell head neck cancer . II . Compare correlation epidermal growth factor receptor density response progression-free survival patient . III . Determine steady state serum level monoclonal antibody C225 frequency human antibody response monoclonal antibody patient treat combination therapy . OUTLINE : This randomize , double-blind , placebo-controlled study . Patients stratify accord disease status ( newly diagnose vs recurrent ) ECOG status ( 0 vs 1 ) . Patients randomize 1 2 treatment arm . Arm I : Patients receive monoclonal antibody C225 IV 2 hour follow 1 hour later cisplatin IV 2 hour day 1 course 1 . Monoclonal antibody C225 administer 1 hour subsequent course . Arm II : Patients receive placebo IV 2 hour follow 1 hour later cisplatin arm I day 1 course 1 . Placebo administer 1 hour subsequent course . Treatment continue every 4 week least 6 course absence disease progression unacceptable toxicity . Arm II patient develop disease progression may crossover arm I treatment . Patients follow 1 3 month every 3 month disease progression . PROJECTED ACCRUAL : A total 114 patient accrue study within 14 month .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven squamous cell carcinoma head neck incurable surgery radiotherapy No nasopharyngeal primary Measurable evaluable disease Newly diagnose extensive , incurable local regional disease AND distant metastasis OR Local regional recurrence/persistence distant metastases surgery radiotherapy Persistent progressive disease radiotherapy must histologically prove least 8 week therapy No brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hemoglobin least 10 g/dL ( transfusion allow ) Hepatic : Bilirubin great 1.5 mg/dL SGOT SGPT great 2 time upper limit normal ( ULN ) Alkaline phosphatase great 2 time ULN Renal : Creatinine great 1.2 mg/dL OR Creatinine clearance least 50 mL/min Calcium great ULN No history hypercalcemia Other : No active infection No concurrent malignancy within past 2 year except curatively treat basal cell squamous cell skin cancer carcinoma situ cervix No known hypersensitivity murine proteins Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior chimeric antibody kinase inhibitor recurrent metastatic disease No 1 prior biotherapy regimen recurrent metastatic disease Chemotherapy : At least 3 month since prior induction adjuvant chemotherapy concurrent radiotherapy No prior chemotherapy recurrent disease Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 4 week since prior radiotherapy Surgery : See Disease Characteristics Recovered prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>untreated metastatic squamous neck cancer occult primary</keyword>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
</DOC>